Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • North Dakota - United States Medical cannabis bill relating to hospice care signed by governor…
  • Lithuania THC to be banned in all tobacco products as of 1st April…
  • District of Columbia - United States Medical cannabis bill increasing access becomes law…
  • United States - Washington Interstate cannabis trade bill passes Senate and heads to House…
  • South Dakota - United States Governor vetoes industrial hemp revision bill…
  • South Dakota - United States Medical cannabis use prohibited if pregnant or breastfeeding…
  • South Dakota - United States Governor signs bill on medical cannabis qualifying conditions…
  • Oklahoma - United States Medical cannabis-related bill passes Senate…
  • Kentucky - United States Delta-8 THC bill signed by governor and becomes law…
  • Europe EC reveals environmental claims proposal…
  • Spain Parties rally behind Podemos proposal for hemp regulation…
  • Maryland - United States Personal use cannabis good, ‘volume dealing’ bad, House says…
View all
News analysis

Curaleaf in hot water with FDA over ‘improper health claims’

Written by || 25th July 2019 || News analysis | Regulation and legislation | North America United States

The US FDA has issued a warning to Curaleaf, which it says is selling CBD products with improper claims to treat diseases like cancer, withdrawal from opioids, pain, and anxiety ...

Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us

Related contents
Mainstream US drugstore chains announce plans to sell CBD
CBD-Intel regulatory news in brief
FDA wades in with guidance on CBD – and warnings over ‘deceptive’ claims

CannIntelligence.com provides independent, in-depth regulatory and market data and intelligence for the global cannabis and cannabinoid sector.

© 2023 Tamarind Media Limited (T/A CannIntelligence)
CannIntelligence does not provide legal, strategic or investment advice. Tamarind Media Limited, the publisher of CannIntelligence, does not accept any liability or responsibility for information or views published.